Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Top 5 Health Care Stocks That Are Preparing To Pump In November

Published 03/11/2023, 12:28
Updated 03/11/2023, 13:40
© Reuters.  Top 5 Health Care Stocks That Are Preparing To Pump In November
HCSG
-
GTHX
-
BTAI
-
EVLO
-
ARQT
-

Benzinga - by Lisa Levin, Benzinga Editor.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Better Therapeutics Inc (NASDAQ: BTTX)

  • Better Therapeutics recently announced the launch of AspyreRxTM to treat adults with Type 2 diabetes. The company’s stock has a 52-week low of $0.14 .
  • RSI Value: 27.85
  • BTTX Price Action: Shares of Better Therapeutics fell 6.1% to close at $0.15 on Thursday.
Heart Test Laboratories Inc (NASDAQ: HSCS)
  • On Sept. 18, Heart Test Laboratories entered into an equity distribution agreement with Maxim Group as sales agent. It has a 52-week low of $0.20.
  • RSI Value: 26.80
  • HSCS Price Action: Shares of Heart Test Laboratories fell 8.2% to close at $0.21 on Thursday.
SINTX Technologies Inc (NASDAQ: SINT)
  • SINTX Technologies was awarded Phase II NIH grant of $1,972,826 for silicon nitride-PEEK 3D printed composite spinal implants. The company’s stock has a 52-week low of $0.40.
  • RSI Value: 28.18
  • SINT Price Action: Shares of SINTX Technologies fell 6.9% to close at $0.42 on Thursday.
Evelo Biosciences Inc (NASDAQ: EVLO)
  • Evelo Biosciences reported the primary endpoint in its Phase 2 clinical study with EDP2939 in moderate psoriasis was not achieved. The company also initiated a process to explore strategic alternatives. The company’s 52-week low is $0.30.
  • RSI Value: 15.98
  • EVLO Price Action: Shares of Evelo Biosciences fell 19.4% to close at $0.31 on Thursday.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)
  • Arcutis Biotherapeutics announced the pricing of a $100 million public offering of 32.5 million common shares at $2.50 per share. The company has a 52-week low of $2.13.
  • RSI Value: 21.70
  • ARQT Price Action: Shares of Arcutis Biotherapeutics fell 1.8% to close at $2.22 on Thursday.

Read More: Fear & Greed Index Remains In 'Fear' Zone; Dow Notches Best Day Since June

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.